STEM-Space™

Our platform goal is to unlock broad, reliable access to cell-based cures by uniting proven HLA biology with next-generation manufacturing and biobanking.

3 Key Challenges With Current Cell Manufacturing

Unhealthy autologous patient cells yields poor quality of raw source material.

Focusing on cell type doesn’t capture rare cell subtypes affecting desired potency.

Lower rate of cell expansion limits manufacturing scale adding to high costs.

Allogeneic 'Yet' Personalized Platform

1. Next-Gen Stem Cell Manufacturing Technology

Cell BioEngines’ discovers cell therapies faster and more efficiently than previous biotech outfits, by relying heavily on scalable manufacturing of clinical-grade HAPLO-HSCs, HAPLO-IMX (Immune Cells) and HAPLO-iPS cell lines from a single source raw material - HLA homozygous cord blood via multiple patented chemical or biological programming methods.

2. Precision Histocompatibility for Immune Integration

In a landscape dominated by autologous products with logistical constraints and engineered allogeneic systems burdened by multi-step editing and regulatory challenges, our platform leverages naturally HLA-matched, transgene-free homozygous cord blood stem cells to minimize immune rejection without complex genetic engineering.

3. Population-aligned Therapeutic Cell Biobank

Cell BioEngines’ differentiates itself with a clinically validated, population-guided HAPLO-donor cord blood unit selection strategy for maximum coverage and a therapeutic master cell biobank. They are not fully universal, but they are a strategic intermediate - offering a practical path toward scalable, population-matched allogeneic therapies with a genomically stable alternative.

Platform Differentiation

Cord–derived healthy stem cell raw material
Inherent superior biological properties to deliver potent therapeutics
Clinically safe and genetically stable alternative
Off-the-shelf solution for rapid delivery within days
Scalable manufacturing of multiple doses from one cord unit
Improved dosing economics

Mapping the tumor microenvironment by single-cell genomics to reveal specialized population of immune cells amenable to therapeutic intervention.

Vishwakarma et al, Nature Communications Biology (2021)

Disruptive CGT technology assets under management

"We leverage the natural developmental biology of stem cells for large scale manufacturing. Each cord unit allows 10-100’s of doses per manufacturing run providing unparalleled scalability" - Founder & CEO, Dr. Ajay Vishwakarma

Learn more